Cargando…

Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study

OBJECTIVE: We studied the effects of LTBP4 and SPP1 polymorphisms on age at loss of ambulation (LoA) in a multiethnic Duchenne muscular dystrophy (DMD) cohort. METHODS: We genotyped SPP1 rs28357094 and LTBP4 haplotype in 283 of 340 participants in the Cooperative International Neuromuscular Research...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bello, Luca, Kesari, Akanchha, Gordish-Dressman, Heather, Cnaan, Avital, Morgenroth, Lauren P, Punetha, Jaya, Duong, Tina, Henricson, Erik K, Pegoraro, Elena, McDonald, Craig M, Hoffman, Eric P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403971/ https://www.ncbi.nlm.nih.gov/pubmed/25641372 http://dx.doi.org/10.1002/ana.24370

Ejemplares similares

Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS).
por: Thangarajh, Mathula, et al.
Publicado: (2018)

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
por: McDonald, Craig M, et al.
Publicado: (2021)

Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
por: Hogarth, Marshall W., et al.
Publicado: (2017)

Somatic mosaicism for Duchenne dystrophy: Evidence for genetic normalization mitigating muscle symptoms
por: Kesari, Akanchha, et al.
Publicado: (2009)

Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019)

Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy
por: Fang, Yuan, et al.
Publicado: (2023)

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019)

Genetic modifiers of upper limb function in Duchenne muscular dystrophy
por: Sabbatini, Daniele, et al.
Publicado: (2022)

Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
por: Hoffman, Eric P., et al.
Publicado: (2019)

The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice
por: Sali, Arpana, et al.
Publicado: (2013)

The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD
por: Duong, Tina, et al.
Publicado: (2021)

Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
por: Larkindale, Jane, et al.
Publicado: (2017)

Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2015)

Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
por: Goemans, Nathalie, et al.
Publicado: (2020)

Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020)

Genetic modifiers of respiratory function in Duchenne muscular dystrophy
por: Bello, Luca, et al.
Publicado: (2020)

Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study
por: Boca, Simina M., et al.
Publicado: (2016)

24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy
por: Mazzone, Elena Stacy, et al.
Publicado: (2013)

Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy
por: Dadgar, Sherry, et al.
Publicado: (2014)

Effect of pelvic fixation on ambulation in children with neuromuscular scoliosis
por: Drake, Luke, et al.
Publicado: (2022)

Lamin A/C–mediated neuromuscular junction defects in Emery-Dreifuss muscular dystrophy
por: Méjat, Alexandre, et al.
Publicado: (2009)

Correction: 24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy
por: Mazzone, Elena Stacy, et al.
Publicado: (2013)

Correction: Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study
por: Boca, Simina M., et al.
Publicado: (2016)

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2016)

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children
por: Hathout, Yetrib, et al.
Publicado: (2016)

Evaluation of Cardiac, Autonomic Functions in Ambulant Patients with Duchenne Muscular Dystrophy
por: Nayak, Amritharekha, et al.
Publicado: (2023)

The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys
por: Pane, Marika, et al.
Publicado: (2014)

Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability?
por: Pane, Marika, et al.
Publicado: (2023)

Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy
por: Bello, Luca, et al.
Publicado: (2016)

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
por: Smith, Edward C., et al.
Publicado: (2020)

Preserved thenar muscles in non‐ambulant Duchenne muscular dystrophy patients
por: Naarding, Karin J., et al.
Publicado: (2021)

Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy
por: Zambon, Alberto A., et al.
Publicado: (2022)

Proteomic profiling of glucocorticoid-exposed myogenic cells: Time series assessment of protein translocation and transcription of inactive mRNAs
por: Reeves, Erica KM, et al.
Publicado: (2009)

Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes
por: Pane, Marika, et al.
Publicado: (2014)

The “Usual Suspects”: Genes for Inflammation, Fibrosis, Regeneration, and Muscle Strength Modify Duchenne Muscular Dystrophy
por: Bello, Luca, et al.
Publicado: (2019)

Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53
por: Brogna, Claudia, et al.
Publicado: (2019)

Correction: Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes
por: Pane, Marika, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ar7sp0n1d6pdjle6ph3f2ncoou